Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Plus Therapeutics's Rhenium (186Re) Obisbemeda?
Rhenium (186Re) Obisbemeda is a small molecule commercialized by Plus Therapeutics, with a leading Phase II program in Leptomeningeal Disease...